Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance
The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Aditxt shares are trading higher by 65.6% during Tuesday's session. The company announced it submitted an application for four new federal funding opportunities.
Aditxt (NASDAQ: ADTX) through its wholly owned subsidiary Adivir, Inc., is progressing with its planned acquisition of Appili Therapeutics (TSX: APLI; OTCPink: APLIF) under a court-approved plan of arrangement. Appili shareholders have overwhelmingly approved the transaction, and the company has secured all necessary court approvals. The closing remains contingent on Aditxt securing sufficient financing, with an extension granted until March 31, 2025, in exchange for a $250,000 payment. Separately, Appili has applied for up to $117.5 million in U.S. federal funding to support infectious disease treatments, further positioning the company within the critical biopharmaceutical sector.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Aditxt (NASDAQ: ADTX), a health innovation platform, provided a corporate update highlighting progress across its subsidiaries and acquisition initiatives. The company remains focused on advancing its autoimmune treatment subsidiary Adimune , precision diagnostics unit Pearsanta , and neurological monitoring subsidiary Adivue , while also pursuing strategic acquisitions, including Appili Therapeutics and Evofem Biosciences. Additionally, Aditxt will launch its Aditxt Weekly Update series on March 21, 2025, featuring CEO Amro Albanna and Evofem CEO Saundra Pelletier, aiming to enhance transparency and investor engagement.
Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today provided a corporate update outlining recent achievements and strategic milestones across its subsidiaries and strategic acquisition initiatives. In addition, the Company will be launching Aditxt Weekly Updates, starting Friday March 21, 2025, and continuing throughout the second quarter of 2025.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report.
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
